Search | Clinical Trials Finder

Conditions: Non Small Cell Lung Cancer
Interventions: [18F]F AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Palo Alto, California • Sacramento, California • Stony Brook, New York

Conditions: Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
Interventions: Durvalumab, External Beam Radiation Therapy, Tremelimumab; Biological · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumors
Interventions: Avelumab; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 53
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more

Conditions: Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Atezolizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Duarte, California • La Jolla, California • Santa Monica, California + 9 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 55
States / cities: Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more

Conditions: Advanced Melanoma
Interventions: lenvatinib, pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Chandler, Arizona • Santa Monica, California • Park Ridge, Illinois + 3 more

Conditions: Glioblastoma
Interventions: Bevacizumab, PD-L1 t-haNK, N-803, Tumor Treating Fields (TTFields, 200 kHz); Drug · Device
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 4
States / cities: El Segundo, California • Fullerton, California • Newport Beach, California + 1 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection; Diagnostic Test · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 18
States / cities: Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Cabozantinib, Everolimus, Lenvatinib, Questionnaire Administration; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • Houston, Texas • Charlottesville, Virginia

Conditions: Endometrial Cancer, Ovarian Cancer
Interventions: PD-1/PDL-1 staining; Diagnostic Test
Lead sponsor: RWJ Barnabas Health at Jersey City Medical Center; Other
Eligibility: Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Non-small Cell Lung Cancer
Interventions: fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 29
States / cities: Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Dupilumab, PD-1/PD-L1 blockade, Anakinra; Drug
Lead sponsor: Thomas Marron; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: SGN-2FF, pembrolizumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more

Conditions: Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Interventions: JDQ443; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
Interventions: Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT); Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 45
States / cities: Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more

Conditions: Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors
Interventions: Nivolumab, Relatlimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: Atezolizumab, Hu5F9-G4; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Sacramento, California • New Haven, Connecticut • New York, New York + 1 more

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Cisplatin, Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,063 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: MEDI4736, tremelimumab, AZD9150; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: La Jolla, California • Baltimore, Maryland • Albuquerque, New Mexico + 5 more

Conditions: Melanoma
Interventions: Nivolumab, Ipilimumab; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Solid Tumors
Interventions: M6223, Bintrafusp alfa; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Nashville, Tennessee • Houston, Texas • San Antonio, Texas

Conditions: Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab; Drug · Biological · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Goodyear, Arizona • Corona, California • Duarte, California + 10 more

Conditions: Head and Neck Neoplasms
Interventions: Pembrolizumab, Placebo, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy, Standard Fractionation (SFX) Radiotherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 24
States / cities: Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more

Search by objective public record fields.

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Tumor Grade Determines PD-1/PDL-1 Expression

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Dupilumab_Metastatic NSCLC

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

First in Human Study of M6223

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)